In details, we have evidenced that: i) ghrelin and leptin levels are lower in CHC patients than in those with T2D, ii) IL-1α, insulin and PAI-1 levels are higher in CHC patients than in those with T2D, iii) CXCL1, CXCL9, β-NGF, C-peptide, GIP and adiponectin are higher only in CHC patients and iv) HGF and glucagon are higher only in T2D patients. This evidence concerns the gene SERPINE1 and type 2 diabetes mellitus.